Trials / Completed
CompletedNCT06101160
Botulinum Toxin Injection for Sialorrhea in Cerebral Palsy
Long-term Follow-up of Safety and Efficacy of OnabotulinumtoxinA for Treatment of Sialorrhea in Juvenile Cerebral Palsy
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 61 (actual)
- Sponsor
- Cairo University · Academic / Other
- Sex
- All
- Age
- 4 Years – 12 Years
- Healthy volunteers
- —
Summary
A 100 units of botulinum toxin was injected in both parotid and submandibular glands for children (2 - 12 years) with incapacitating sialorrhea in juvenile cerebral palsy patients and they are followed up for 1 year
Detailed description
This was a prospective, longitudinal analysis with 1-year follow-up of 52 children with juvenile cerebral palsy (JCP) suffering from sialorrhea enrolled from 3 tertiary pediatric neurology rehabilitation centers (two in Cairo and one in Alexandria) and subjected to repeated BoNT-A injection. The recruitment period was between June 30, 2021, until May 1, 2022 (the last patient follow-up ended on April 30, 2023). Intervention: 100 units of OnabotulinumtoxinA (Botox®) were injected in the parotid and submandibular glands Follow-up visits: mo 1 post-injection (for every injection session) and every 3 months thereafter In each visit; the following efficacy variables were assessed: Primary outcome measures: The severity and frequency of sialorrhea evaluated by Drooling Severity Scale (DSS), and Drooling Frequency Scale (DFS) and visual-analogic ratings of familial distress (VAS-FD). Secondary outcome measure: The carers' Global Impression of Change Scale score measured on a 7-point Likert scale from -3 (very much worse) to +3 (very much improved) Also, adverse events were assessed in each visit
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | onaBoNT-A | injection under ultrasonography |
Timeline
- Start date
- 2021-06-30
- Primary completion
- 2022-05-01
- Completion
- 2023-04-30
- First posted
- 2023-10-26
- Last updated
- 2023-10-27
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT06101160. Inclusion in this directory is not an endorsement.